免疫抑制受体激动剂治疗药物
Rustin R Lovewell1, Solomon Langermann1, Dallas B Flies1
1NextCure, Beltsville, MD, United States.
Frontiers in immunology
|April 10, 2025
概括
激活免疫抑制受体 (IIRs) 为疾病提供了尚未开发的治疗潜力. 本综述探讨了IIR激动剂治疗的最新进展,为药物开发提出了新的细胞活动概念.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 免疫系统使用抑制和刺激受体来维持健康.
- 目前的疗法经常对抗免疫受体,在癌症和自身免疫方面取得了成功.
- 对激素治疗,特别是对免疫抑制受体 (IIRs) 存在显著的潜力.
研究的目的:
- 审查针对免疫抑制受体 (IIR) 途径的治疗方法的近期临床前和临床进展.
- 突出IIR激动剂治疗药物治疗各种疾病的潜力.
- 提出一个新的概念框架,以了解细胞水平的IIR激动剂活性.
主要方法:
- 关于IIR激动剂治疗药物的临床前和临床研究的文献综述.
- 分析涉及免疫受体调节的治疗策略.
- 细胞活动框架的开发:刺激细胞的激素抑制 (SuSt) 和抑制细胞的激素抑制 (SuSu).
主要成果:
- 在开发IIR激动剂治疗药物方面取得了重大进展.
- IIR激动剂在疾病治疗方面显示出相当大的未开发潜力.
- 提出了一个新的概念框架 (SuSt/SuSu) 来分类IIR激动机制.
结论:
- 治疗IIR激动剂是一种有前途的药物开发前沿.
- 在细胞水平上了解IIR激动机制可以指导未来的治疗策略.
- 拟议的SuSt和SuSu概念为IIR抗激素活性提供了新的视角.
相关概念视频
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Eukaryotic Transcription Inhibitors
9.7K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.7K
Drug-Receptor Interaction: Antagonist
2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Combined Effects of Drugs: Antagonism
8.1K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.1K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103


